Phaseline

Companies › Everest Medicines (China)

Everest Medicines (China): clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 2; Oncology, Genitourinary; next expected readout Dec 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
EVER001
Acts on multiple immune pathways without directly affecting T cells or depleting B cells
–Phase 2Minimal Change Disease (MCD)Dec 2028
EVM14
Cancer vaccine
–Phase 1Selected Types of Solid TumorNov 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07614477EVER001Phase 2Minimal Change Disease (MCD)GenitourinaryDec 2028
NCT07095868EVM14Phase 1Selected Types of Solid TumorOncologyNov 2029

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Calico Life Sciences Alentis Therapeutics Shenzhen Kangzhe Biotechnology iTeos Therapeutics LG Chem

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.